Differences between Trypanosoma brucei gambiense groups 1 and 2 in their resistance to killing by trypanolytic factor 1.

PLoS Negl Trop Dis

College of Medical, Veterinary and Biological Sciences, Wellcome Trust Centre for Molecular Parasitology, University of Glasgow, Glasgow, United Kingdom.

Published: September 2011

Background: The three sub-species of Trypanosoma brucei are important pathogens of sub-Saharan Africa. T. b. brucei is unable to infect humans due to sensitivity to trypanosome lytic factors (TLF) 1 and 2 found in human serum. T. b. rhodesiense and T. b. gambiense are able to resist lysis by TLF. There are two distinct sub-groups of T. b. gambiense that differ genetically and by human serum resistance phenotypes. Group 1 T. b. gambiense have an invariant phenotype whereas group 2 show variable resistance. Previous data indicated that group 1 T. b. gambiense are resistant to TLF-1 due in-part to reduced uptake of TLF-1 mediated by reduced expression of the TLF-1 receptor (the haptoglobin-hemoglobin receptor (HpHbR)) gene. Here we investigate if this is also true in group 2 parasites.

Methodology: Isogenic resistant and sensitive group 2 T. b. gambiense were derived and compared to other T. brucei parasites. Both resistant and sensitive lines express the HpHbR gene at similar levels and internalized fluorescently labeled TLF-1 similar fashion to T. b. brucei. Both resistant and sensitive group 2, as well as group 1 T. b. gambiense, internalize recombinant APOL1, but only sensitive group 2 parasites are lysed.

Conclusions: Our data indicate that, despite group 1 T. b. gambiense avoiding TLF-1, it is resistant to the main lytic component, APOL1. Similarly group 2 T. b. gambiense is innately resistant to APOL1, which could be based on the same mechanism. However, group 2 T. b. gambiense variably displays this phenotype and expression does not appear to correlate with a change in expression site or expression of HpHbR. Thus there are differences in the mechanism of human serum resistance between T. b. gambiense groups 1 and 2.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3167774PMC
http://dx.doi.org/10.1371/journal.pntd.0001287DOI Listing

Publication Analysis

Top Keywords

group gambiense
28
human serum
12
resistant sensitive
12
sensitive group
12
gambiense
11
group
11
trypanosoma brucei
8
gambiense groups
8
serum resistance
8
hphbr gene
8

Similar Publications

Prevalence of dermal trypanosomes in suspected and confirmed cases of gambiense human African trypanosomiasis in Guinea.

PLoS Negl Trop Dis

August 2024

Trypanosome Transmission Group, Trypanosome Cell Biology Unit, INSERM U1201, Department of Parasites and Insect Vectors, Institut Pasteur, Université Paris Cité, Paris, France.

Article Synopsis
  • The study investigates the presence of African trypanosomes in the skin of individuals at risk for gambiense Human African Trypanosomiasis (gHAT) in Guinea, finding that a significant number of seropositive individuals carry the parasites in their dermal layers.
  • Out of nearly 19,000 screened participants, 96 were included, revealing dermatological symptoms to be more common in seropositive individuals compared to seronegative ones.
  • Follow-up showed a decrease in skin parasite detection post-treatment, but a notable percentage of untreated seropositive individuals continued to test positive, highlighting potential challenges in achieving gHAT elimination.
View Article and Find Full Text PDF

Background: Serological screening tests play a crucial role to diagnose gambiense human African trypanosomiasis (gHAT). Presently, they preselect individuals for microscopic confirmation, but in future "screen and treat" strategies they will identify individuals for treatment. Variability in reported specificities, the development of new rapid diagnostic tests (RDT) and the hypothesis that malaria infection may decrease RDT specificity led us to evaluate the specificity of 5 gHAT screening tests.

View Article and Find Full Text PDF

Trypanosoma brucei gambiense (Tbg) group 2 is a subgroup of trypanosomes able to infect humans and is found in West and Central Africa. Unlike other agents causing sleeping sickness, such as Tbg group 1 and Trypanosoma brucei rhodesiense, Tbg2 lacks the typical molecular markers associated with resistance to human serum. Only 36 strains of Tbg2 have been documented, and therefore, very limited research has been conducted despite their zoonotic nature.

View Article and Find Full Text PDF

The evolving spectrum of human African trypanosomiasis.

QJM

June 2024

School of Psychology and Neuroscience, College of Medical, Veterinary and Life Sciences, University of Glasgow, Wellcome Surgical Institute, Garscube Campus, Glasgow G61 1QH, UK.

Article Synopsis
  • Human African trypanosomiasis (HAT), or sleeping sickness, poses a significant health threat in 36 sub-Saharan African countries, affecting up to 60 million people, but recent efforts have led to a dramatic decline in cases.
  • Improved diagnostic methods and treatment options, such as the nifurtimox-eflornithine combination therapy (NECT) and oral fexinidazole, have been developed, enhancing patient outcomes.
  • While the World Health Organization's initial goal of reducing HAT as a public health issue by 2020 has likely been met, achieving the more ambitious target of interrupting transmission by 2030 remains uncertain.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!